Banu Özveri Koyuncu1, Gözde Işık2, Meltem Özden Yüce2, Sevtap Günbay2, Tayfun Günbay2. 1. Department of Oral Surgery, Faculty of Dentistry, Ege Univeristy, Bornova, İzmir, Turkey. banuozverikoyuncu@yahoo.com. 2. Department of Oral Surgery, Faculty of Dentistry, Ege Univeristy, Bornova, İzmir, Turkey.
Abstract
BACKGROUND: The aim of this prospective study was to assess the effectiveness of concentrated growth factors (CGF) in preventing the development of alveolar osteitis (AO) after the extraction of partially-erupted mandibular third molars. METHODS:Seventy patients (26 men and 44 women) 18 years or older (mean age 25.86; range 18-35) underwent 140 third molar extractions. All the patients presented with bilateral, partially-erupted mandibular third molars and underwent surgical extractions. In each case, one socket received CGF and the other served as a control. The predictor variable was the CGF application and the sides were categorized as 'CGF' and 'non-CGF'. The outcome variable was the development of AO during the first postoperative week. Other study variables included age and gender. Data were analyzed using Cochran's Q test with the significance level set at a P value less than 0.05. RESULTS: The overall frequency of AO was 11.4% for the control group. The frequency of AO in the CGF group was significantly lower than in the non-CGF group (p < 0.001). CONCLUSIONS: Based on the results of this study, application of CGF fibrin gel may decrease the risk of AO development after mandibular third molar surgery. TRIAL REGISTRATION: This study was registered in ClinicalTrials.gov database on November 1, 2019 (ID: NCT04151147 , retrospectively registered).
RCT Entities:
BACKGROUND: The aim of this prospective study was to assess the effectiveness of concentrated growth factors (CGF) in preventing the development of alveolar osteitis (AO) after the extraction of partially-erupted mandibular third molars. METHODS: Seventy patients (26 men and 44 women) 18 years or older (mean age 25.86; range 18-35) underwent 140 third molar extractions. All the patients presented with bilateral, partially-erupted mandibular third molars and underwent surgical extractions. In each case, one socket received CGF and the other served as a control. The predictor variable was the CGF application and the sides were categorized as 'CGF' and 'non-CGF'. The outcome variable was the development of AO during the first postoperative week. Other study variables included age and gender. Data were analyzed using Cochran's Q test with the significance level set at a P value less than 0.05. RESULTS: The overall frequency of AO was 11.4% for the control group. The frequency of AO in the CGF group was significantly lower than in the non-CGF group (p < 0.001). CONCLUSIONS: Based on the results of this study, application of CGF fibrin gel may decrease the risk of AO development after mandibular third molar surgery. TRIAL REGISTRATION: This study was registered in ClinicalTrials.gov database on November 1, 2019 (ID: NCT04151147 , retrospectively registered).
Entities:
Keywords:
Alveolar osteitis; Concentrated growth factors; Platelet concentrates; Third molar surgery
Authors: Jeong Woo Lee; O Hyun Kwon; Taek Kyun Kim; Young Kyoo Cho; Kang Young Choi; Ho Yun Chung; Byung Chae Cho; Jung Dug Yang; Jun Ho Shin Journal: Arch Plast Surg Date: 2013-09-13
Authors: Sadam Ahmed Elayah; Xiang Liang; Karim Ahmed Sakran; Linyang Xie; Hamza Younis; Ahmed Es Alajami; Junbo Tu; Sijia Na Journal: BMC Oral Health Date: 2022-08-30 Impact factor: 3.747